EP0960139A1 - Elastomer treatment process to decrease peroxide levels - Google Patents

Elastomer treatment process to decrease peroxide levels

Info

Publication number
EP0960139A1
EP0960139A1 EP98904880A EP98904880A EP0960139A1 EP 0960139 A1 EP0960139 A1 EP 0960139A1 EP 98904880 A EP98904880 A EP 98904880A EP 98904880 A EP98904880 A EP 98904880A EP 0960139 A1 EP0960139 A1 EP 0960139A1
Authority
EP
European Patent Office
Prior art keywords
epdm
peroxide
mercaptoethanol
treated
reducing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98904880A
Other languages
German (de)
French (fr)
Other versions
EP0960139A4 (en
EP0960139B1 (en
Inventor
Karl M. Gelotte
Joseph D'silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Rhone Poulenc Rorer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharmaceuticals Inc filed Critical Rhone Poulenc Rorer Pharmaceuticals Inc
Priority to SI9830622T priority Critical patent/SI0960139T1/en
Publication of EP0960139A1 publication Critical patent/EP0960139A1/en
Publication of EP0960139A4 publication Critical patent/EP0960139A4/en
Application granted granted Critical
Publication of EP0960139B1 publication Critical patent/EP0960139B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F6/00—Post-polymerisation treatments
    • C08F6/26—Treatment of polymers prepared in bulk also solid polymers or polymer melts
    • C08F6/28—Purification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/04—Reduction, e.g. hydrogenation

Definitions

  • This invention relates to a process to reduce the residual peroxide levels in crosslinked ethylene-propylene diene monomer (EPDM) elastomer material and to inhalation devices containing EPDM gaskets made by the inventive process.
  • EPDM ethylene-propylene diene monomer
  • Metered-dose inhalers are commonly used to deliver medicaments to the respiratory system, particularly asthma and allergy medicaments.
  • a metered-dose inhaler When a metered-dose inhaler is filled with medicament and shaken, the EPDM components are in direct contact with the medicament. The medicament is thus exposed to any residual peroxides in the gasket material. Applicants have found that these residual peroxides can cause significant oxidative degradation of the medicament. The longer the medicament is stored in the metered-dose inhaler in contact with the EPDM material, the more degradation occurs. Thus, the concentration of medicament significantly diminishes with storage time in the metered dose inhaler. This causes non-uniformity in patient dosing, because different dosages of medicament will be delivered with one inhaler actuation depending on how long the medicament has been stored in the inhaler.
  • the peroxide may be reduced by use of different peroxide crosslink initiators during elastomer formulation or optimization of the elastomer curing process.
  • the advantage of the present invention is that residual peroxides can be virtually eliminated with relative ease without the need to modify elastomer formulations or curing conditions. This avoids the need to retool the elastomer production process or to submit new information to regulatory agencies because of a change in formulation.
  • Applicants' invention may be used in conjunction with other methods to further reduce residual peroxide levels.
  • Applicants have identified a major cause of medicament degradation in medicaments stored in metered-dose inhalers and have invented a method to prevent or greatly reduce degradation.
  • the EPDM valve components are exposed to a solution of a chemical reducing agent, such as an ethanolic solution of 2-mercaptoethanol.
  • the reducing agent greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups.
  • EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler.
  • An advantage of this process is that the treated EPDM gasket material retains its favorable physical properties and its good performance in metering valves.
  • Figure 1 is a graph showing the percentage of the theoretical amount present of medicament glucocorticoid versus the level of residual peroxide.
  • Figure 2 is a graph showing the concentration of degradation products versus the level of residual peroxide.
  • the invention concerns an effective process to make the EPDM elastomer used for metering valve gasket and seats much more compatible with the pharmaceutical formulation inside the inhaler.
  • the EPDM elastomeric components are treated with a chemical reducing agent to eliminate residual peroxides.
  • the reducing agent is then removed by solvent washes and/or air drying.
  • the invention may be used on metered-dose inhalers for use with any pharmaceutical product that is degraded or otherwise detrimentally impacted by the presence of peroxide.
  • the invention is used on inhalers for the delivery of glucocorticoids, more preferably on glucocorticoids having a methylthio group susceptible to oxidative degradation.
  • glucocorticoids more preferably on glucocorticoids having a methylthio group susceptible to oxidative degradation.
  • Such compounds are used in the treatment of bronchial asthma. They have been shown to be chemically unstable when stored for three weeks or more in a metered-dose inhaler having EPDM gaskets. Exposure of glucocorticoid to peroxide, an effective oxidizing agent, is known to degrade it by oxidative pathways. The treatment process described in this application greatly diminishes the peroxide level of EPDM valve elastomer material and, therefore, greatly improves the chemical stability of the drug product.
  • the invention may be used on any polymeric material that contains residual amounts of peroxide.
  • residual amounts as amounts of 5% or less by weight of the polymeric material.
  • the EPDM elastomer is composed of the base EPDM polymer, several inorganic filler materials, and a dialkyl peroxide to initiate polymer crosslinking.
  • the crosslinker initiates formation of covalent bonds between adjacent EPDM polymer molecules during the formulation curing (heating) process, yielding an elastomeric ("rubbery”) material.
  • any compound capable of peroxide reduction may be used under the invention as the chemical reducing agent.
  • compounds containing sulfur in one of its lower valence states are used. More preferably, thiol compounds such as 2-mercaptoethanol and sulfur dioxide are used.
  • a solution of acetic acid and chloroform was prepared by mixing three parts by volume of glacial acetic acid with two parts by volume of chloroform, U.S. P. grade.
  • a saturated solution of potassium iodide was prepared in water. The solution was saturated as evidenced by the presence of undissolved crystals. The solution was stored in the dark.
  • a solution of sodium thiosulfate, 0.1 N was prepared and accurately standardized.
  • a solution of sodium thiosulfate, 0.01 N was prepared and accurately standardized.
  • a solution of thyodene indicator was prepared.
  • EPDM samples of equal mass were placed into MDI canisters containing 15mL of a 2.0 mg/mL solution of (20R)-16 , 17 ⁇ -Butylidenedioxy-6 ⁇ , 9 ⁇ -difluoro-l l ⁇ -hydroxy-17 ⁇ - (methylthio)androst-4-ene-3-one in a vehicle of 10% w/w anhydrous ethanol in 1,1,1,2- tetrafluoroethane.
  • the following samples were used:
  • EPDM gasket - commercial lot B 3. EPDM seats - commercial lot B
  • Butylidenedioxy-6 , 9 -difluoro-l l ⁇ -hydroxy-17 ⁇ -(methylthio)androst-4-ene-3-one upon exposure to EPDM gasket material are sulfoxide diastereoisomers.
  • Monitoring these degradation products is a sensitive way to assess chemical stability of formulations, particularly when drug potency losses are small.
  • Degradation product levels are reported in Table 3. The results showed that application of Applicants' process significantly reduced the amount of degradation products.
  • the glucocorticoid (20R)-16 ⁇ , 17 -Butylidenedioxy-6 ⁇ , 9 -difluoro-l l ⁇ -hydroxy-17 ⁇ - (methylthio)androst-4-ene-3-one, is sensitive to oxidation and degrades largely to the oxidative degradation products of sulfoxide diastereoisomers and "6-keto" derivatives when in the presence of standard formulation media. Exposure of the drug to hydrogen peroxide readily yields these sulfoxides and ultimately the sulfone.
  • Figures 1 and 2 are helpful to show the relationship between EPDM residual peroxide level and (20R)-16 ⁇ , 17 -Butylidenedioxy-6 , 9 -difluoro-l l ⁇ -hydroxy-17 ⁇ -(methylthio)androst-4- ene-3-one stability.
  • Figure 1 clearly demonstrates that drug loss is inversely related, in a linear manner, to residual peroxide level at both analysis time points, three and seven weeks.
  • Figure 2 demonstrates that the sulfoxide degradation product levels increase with residual peroxide level at both time points.

Abstract

A novel process has been developed for the treatment of crosslinked ethylene-propylene diene monomer (EPDM) elastomer material to decrease its residual peroxide levels. EPDM is used to form the seats and neck gaskets of metering valves used in metered-dose inhalers (MDI). For filled and inverted MDI units these EPDM components are in direct contact with the pharmaceutical formulation media. The process involves exposing the EPDM valve components to a solution of 2-mercaptoethanol, a chemical reducing agent. The 2-mercaptoethanol greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups. EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler. An advantage of this approach is that the treated EPDM would likely retain its favorable physical properties and its good performance in metering valves. In this work 2-mercaptoethanol was used as the model reducing agent. It is believed, however, that similar positive results can be obtained using other reducing agents, notably other volatile compounds containing sulfur in one of its lower valence states (i.e. other thiol compounds or sulfur dioxide).

Description

ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS
Background of the Invention
This invention relates to a process to reduce the residual peroxide levels in crosslinked ethylene-propylene diene monomer (EPDM) elastomer material and to inhalation devices containing EPDM gaskets made by the inventive process.
Metered-dose inhalers are commonly used to deliver medicaments to the respiratory system, particularly asthma and allergy medicaments. When a metered-dose inhaler is filled with medicament and shaken, the EPDM components are in direct contact with the medicament. The medicament is thus exposed to any residual peroxides in the gasket material. Applicants have found that these residual peroxides can cause significant oxidative degradation of the medicament. The longer the medicament is stored in the metered-dose inhaler in contact with the EPDM material, the more degradation occurs. Thus, the concentration of medicament significantly diminishes with storage time in the metered dose inhaler. This causes non-uniformity in patient dosing, because different dosages of medicament will be delivered with one inhaler actuation depending on how long the medicament has been stored in the inhaler.
Applicants have considered various approaches to reduce residual peroxides. For example, the peroxide may be reduced by use of different peroxide crosslink initiators during elastomer formulation or optimization of the elastomer curing process. The advantage of the present invention is that residual peroxides can be virtually eliminated with relative ease without the need to modify elastomer formulations or curing conditions. This avoids the need to retool the elastomer production process or to submit new information to regulatory agencies because of a change in formulation. Furthermore, Applicants' invention may be used in conjunction with other methods to further reduce residual peroxide levels.
Summary
Applicants have identified a major cause of medicament degradation in medicaments stored in metered-dose inhalers and have invented a method to prevent or greatly reduce degradation. The EPDM valve components are exposed to a solution of a chemical reducing agent, such as an ethanolic solution of 2-mercaptoethanol. The reducing agent greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups. EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler. An advantage of this process is that the treated EPDM gasket material retains its favorable physical properties and its good performance in metering valves.
Brief Description of the Drawings
Figure 1 is a graph showing the percentage of the theoretical amount present of medicament glucocorticoid versus the level of residual peroxide.
Figure 2 is a graph showing the concentration of degradation products versus the level of residual peroxide.
Detailed Description of the Invention
The invention concerns an effective process to make the EPDM elastomer used for metering valve gasket and seats much more compatible with the pharmaceutical formulation inside the inhaler.
In the process of the invention, the EPDM elastomeric components are treated with a chemical reducing agent to eliminate residual peroxides. The reducing agent is then removed by solvent washes and/or air drying.
The invention may be used on metered-dose inhalers for use with any pharmaceutical product that is degraded or otherwise detrimentally impacted by the presence of peroxide.
Preferably, the invention is used on inhalers for the delivery of glucocorticoids, more preferably on glucocorticoids having a methylthio group susceptible to oxidative degradation. Such compounds are used in the treatment of bronchial asthma. They have been shown to be chemically unstable when stored for three weeks or more in a metered-dose inhaler having EPDM gaskets. Exposure of glucocorticoid to peroxide, an effective oxidizing agent, is known to degrade it by oxidative pathways. The treatment process described in this application greatly diminishes the peroxide level of EPDM valve elastomer material and, therefore, greatly improves the chemical stability of the drug product.
The invention may be used on any polymeric material that contains residual amounts of peroxide. For purposes of this invention, Applicants define residual amounts as amounts of 5% or less by weight of the polymeric material. Of specific interest is the EPDM elastomer used in metering valve seats and gaskets. The EPDM elastomer is composed of the base EPDM polymer, several inorganic filler materials, and a dialkyl peroxide to initiate polymer crosslinking. The crosslinker initiates formation of covalent bonds between adjacent EPDM polymer molecules during the formulation curing (heating) process, yielding an elastomeric ("rubbery") material.
Any compound capable of peroxide reduction may be used under the invention as the chemical reducing agent. Preferably, compounds containing sulfur in one of its lower valence states are used. More preferably, thiol compounds such as 2-mercaptoethanol and sulfur dioxide are used. Experimental Results
Example 1 : Residual Peroxide in EPDM Gaskets
Samples of EPDM gaskets designed for the neck portion of a metered-dose inhaler were treated with 20% 2-mercaptoethanol in ethanol solution for the same amount of time, approximately 3.5 days. The samples were then leached three times in ethanol and allowed to air dry. All treatments were performed at ambient room temperature.
A negative control sample consisting of untreated commercial EPDM neck gasket material was also included for comparison. Treated and control EPDM samples were assessed for residual peroxides by iodometric titration following the procedure described below. The results of samples treated for 3.5 days are given in Table 1. When Applicants' process is used (example 1, Table 1) the EPDM peroxide level is about eight fold less than the level of the untreated EPDM (example 3, Table 1) and about equal to the peroxide level of uncrosslinked EPDM (example 4, Table 1). This is in contrast with the experimental control sample (example 2, Table 1 ) that underwent the same solvent exposure and rinsing steps as the 2-mercaptoethanol treatment sample; the experimental control sample showed essentially identical peroxide levels as the untreated sample. This indicates that the observed reduction in peroxide is attributable to Applicants' inventive process.
Method of Measuring Residual Peroxide
Most organic peroxides are reduced by iodide ions in acid solution, yielding one mole of iodine per equivalent of peroxide.
ROOR' + 21 + 2H20→I2 + ROH + R'OH + 20H
This is the basis of the well-known technique of iodometric titration for quantitation of organic peroxides in which the liberated iodine is titrated with a standard solution of sodium thiosulfate. There are numerous specific variations reported for this method, but all generally apply to liquid or semisolid test media. One complication with application of the iodometric titration method to EPDM is that the sample is a solid rubber matrix, making it difficult to ensure complete reaction with peroxide within the sample matrix.
An accepted iodometric titration method for fats and oils, American Oil Chemists' Society Official Method Cd 8-53, was evaluated for its utility in studying peroxides in EPDM. The method was further developed and modified to render it more suitable to the EPDM system. The method used to measure residual peroxide in EPDM is as follows:
• Reagent Preparation: (1) A solution of acetic acid and chloroform was prepared by mixing three parts by volume of glacial acetic acid with two parts by volume of chloroform, U.S. P. grade. (2) A saturated solution of potassium iodide was prepared in water. The solution was saturated as evidenced by the presence of undissolved crystals. The solution was stored in the dark. (3) A solution of sodium thiosulfate, 0.1 N, was prepared and accurately standardized. (4) A solution of sodium thiosulfate, 0.01 N, was prepared and accurately standardized. (5) A solution of thyodene indicator was prepared. • Procedure: A sample of EPDM was pulverized in a milling device cooled with liquid nitrogen and the smaller particle fractions (about 250 micron and smaller) were collected. A 0.5 g sample of these EPDM smaller particle fractions was placed in a 250 ml Erlenmeyer flask and 30 ml of the acetic-acid chloroform solution was added to the flask. The sample was swirled in the solution with occasional shaking for 1.5 hours. Then 30 ml of distilled water was added. The solution was titrated with 0.1 N sodium thiosulfate according to standard titration practices until the yellow color had almost disappeared. Thyodene indicator solution was added and the titration was continued until the desired color change had just occurred.
Applicants found that this method is reproducible (RSD 0.6%, n=4) and suitable for evaluating peroxide levels in EPDM.
Experiment 2: Relationship Between Residual Peroxide and Glucocorticoid Stability
To determine the effect of peroxide levels on medicament stability, an experiment was carried out using (20R)-16r , 17 -Butylidenedioxy-6 , 9α-difluoro-l l β-hydroxy-17β-(methylthio)androst- 4-ene-3-one (a glucocorticoid sample) and EPDM gaskets used in a metered-dose inhaler. The EPDM gaskets were contacted with 20% w/w 2-mercaptoethanol solutions in either chloroform or ethanol for 3 weeks. The samples were then leached three times with their respective solvents and air dried. Control samples of EPDM were prepared by treating them with the same solvent exposure and drying steps as the 2-mercaptoethanol-treated samples.
EPDM samples of equal mass (0.7g) were placed into MDI canisters containing 15mL of a 2.0 mg/mL solution of (20R)-16 , 17α-Butylidenedioxy-6α, 9α-difluoro-l l β-hydroxy-17β- (methylthio)androst-4-ene-3-one in a vehicle of 10% w/w anhydrous ethanol in 1,1,1,2- tetrafluoroethane. The following samples were used:
1. EPDM gasket - commercial lot A
2. EPDM gasket - commercial lot B 3. EPDM seats - commercial lot B
4. EPDM crosslinked with di-tertbutyl peroxide
5. EPDM crosslinked with dicumyl peroxide
6. EPDM crosslinked with 2,5 bis(tertbutylperoxy) 2,5 dimethyl hexane
7. Uncrosslinked EPDM 8. EPDM gasket - commercial lot A - treated with 2-mercaptoethanol (in ethanol)
9. EPDM gasket - commercial lot A - treated with ethanol only
10. Control - formulation only These samples were stored in the upright (valve up) orientation at 40ϋC. The degradation products were measured using a validated HPLC method. The samples were analyzed after 3 weeks and 7 weeks storage at 40° for amounts of degradation products and evaluated by comparing drug recovery and degradation product levels. Results are reported in Tables 2 and 3.
Earlier work had demonstrated that the major degradation products of (20R)-16α, 17α-
Butylidenedioxy-6 , 9 -difluoro-l lβ-hydroxy-17β-(methylthio)androst-4-ene-3-one upon exposure to EPDM gasket material are sulfoxide diastereoisomers. Monitoring these degradation products is a sensitive way to assess chemical stability of formulations, particularly when drug potency losses are small. Degradation product levels are reported in Table 3. The results showed that application of Applicants' process significantly reduced the amount of degradation products.
The glucocorticoid, (20R)-16α, 17 -Butylidenedioxy-6α, 9 -difluoro-l lβ-hydroxy-17β- (methylthio)androst-4-ene-3-one, is sensitive to oxidation and degrades largely to the oxidative degradation products of sulfoxide diastereoisomers and "6-keto" derivatives when in the presence of standard formulation media. Exposure of the drug to hydrogen peroxide readily yields these sulfoxides and ultimately the sulfone.
It is clear from Tables 2 and 3 that there is less drug loss and lower levels of sulfoxide diastereoisomers in both the alternate peroxide EPDM samples and the dialkyl-peroxide EPDM samples that were treated with 2-mercaptoethanol. The samples prepared according to Applicants' invention (sample 8 in Tables 2 and 3) and stored for seven weeks showed glucocorticoid stability that was about equal to glucocorticoid stability of the samples stored in the solution alone, without any EPDM material present (example 10, Tables 2 and 3). When stability is measured by the occurrence of degradation products, Applicants' invention similarly shows great success. After seven weeks of storage, the sample containing EPDM treated by Applicants' invention showed levels of sulfoxides as low as those found in the control and in the sample with uncrosslinked EPDM.
Figures 1 and 2 are helpful to show the relationship between EPDM residual peroxide level and (20R)-16α, 17 -Butylidenedioxy-6 , 9 -difluoro-l lβ-hydroxy-17β-(methylthio)androst-4- ene-3-one stability. Figure 1 clearly demonstrates that drug loss is inversely related, in a linear manner, to residual peroxide level at both analysis time points, three and seven weeks. Figure 2 demonstrates that the sulfoxide degradation product levels increase with residual peroxide level at both time points. These results indicate that the mechanism of interaction between EPDM and glucocorticoid is oxidative degradation caused by residual peroxide in the EPDM. TABLE 1
PEROXIDE LEVELS OF EPDM NECK GASKETS TREATED WITH REDUCING AGENT
SAMPLE PEROXIDE VALUE (mEq/Kg)
1. EPDM Gasket - Commercial Lot A 28.3 Treated with Reducing Agent
2. EPDM Gasket - Commercial Lot A 220.2 Treated with Ethanol
3. EPDM Gasket - Commercial Lot A 221.9
4. Uncrosslinked EPDM 31.0
TABLE 2
RELATIONSHIP BETWEEN RESIDUAL PEROXIDE AND GLUCOCORTICOID POTENCY
3 Wθθk Point 7 Wθθk Point
SAMPLE PEROXIDE _, % Theory. % Theory . ,_. Glucocortx- Glucocαrtxcoxd* VALUE (mEq/Kg) coiα*
1. EPDM Gasket - Commercial Lot A 221.9 58.33 38.87
2. EPDM Gasket - Commercial Lot B 312.5 38.42 16.8
3. EPDM Seats - Commercial Lot B 178.2 61.43 50.94
4. Di-tertbutyl Peroxide EPDM 40.7 93.21 93.41
5. Dicumyl Peroxide EPDM 37.1 89.77 91.06
6. 2,5 bis(tertbutylperoxy) 52.8 89.24 89.39 2,5 dimethyl hexane EPDM
7. Uncrosslinked EPDM 31.0 90.72 93.510
8. EPDM Gasket - Commercial Lot A Treated with Reducing Agent 28.3 87.51 92.29
9. EPDM Gasket - Commercial Lot A 220.2 58.41 37.47 Treated with Ethanol
10. Control (Upright MDI) I not applicable 93.79 91.93
*(20R)-16α, 17α-Butylidenedioxy-6α, 9α-difluoro-l lβ-hydroxy-17β-(methylthio)androst-4-ene-3-one
Storage Conditions: 40C TABLE 3
RELATIONSHIP BETWEEN RESIDUAL PEROXIDE AND LEVELS OF SULFOXIDE DEGRADATION PRODUCTS
3 Week Point 7 Week Point
SAMPLE PEROXIDE AMT. (MG/G) AMT. (MG/G) VALUE (mEq/Kg) Sulfoxides Sulfoxides
1. EPDM Gasket - Commercial Lot A 221.9 0.485 0.728
2. EPDM Gasket - Commercial Lot B 312.5 0.767 1.1516
3. EPDM Seats - Commercial Lot B 178.2 0.441 0.696
4. Di-tertbutyl Peroxide EPDM 40.7 0.018 0.038
5. Dicumyl Peroxide EPDM 37.1 0.038 0.068
6. 2,5 bis(tertbutylperoxy) 52.8 0.043 0.076 2,5 dimethyl hexane EPDM
7. Uncrosslinked EPDM 31.0 0.009 0.020
8. EPDM Gasket - Commercial Lot A Treated with Reducing Agent 28.3 0.009 0.015
9. EPDM Gasket - Commercial Lot A 220.2 0.492 0.845 Treated with Ethanol
10. Control (Upright MDI) not applicable 0.003 0.014
Storage Conditions: 40C

Claims

ClaimsWe claim:
1. A process for reducing the amount of peroxide present in an elastomer material comprising the step of contacting the material with 2-mercaptoethanol.
2. A process according to claim 1 wherein the material is ethylene-propylene diene monomer elastomer material.
3. A process for treating elastomer material to be used in metered-dose inhalers comprising the step of contacting the elastomer material with a reducing agent.
4. A process according to claim 3 wherein the reducing agent is 2-mercaptoethanol.
5. A process according to claim 1 wherein the material is a gasket material for a metered-dose inhaler for the delivery of a medicament.
6. A process according to claim 5 wherein the medicament is a glucocorticoid.
7. A process according to claim 6 wherein the glucocorticoid is (20R)-16╬▒, 17 - Butylidenedioxy-6 , 9╬▒-difluoro-l l╬▓-hydroxy-17╬▓-(methylthio)androst-4-ene-3-one.
EP98904880A 1997-02-04 1998-02-04 Elastomer treatment process to decrease peroxide levels Expired - Lifetime EP0960139B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9830622T SI0960139T1 (en) 1997-02-04 1998-02-04 Elastomer treatment process to decrease peroxide levels

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3737597P 1997-02-04 1997-02-04
US37375P 1997-02-04
PCT/US1998/002068 WO1998033827A1 (en) 1997-02-04 1998-02-04 Elastomer treatment process to decrease peroxide levels

Publications (3)

Publication Number Publication Date
EP0960139A1 true EP0960139A1 (en) 1999-12-01
EP0960139A4 EP0960139A4 (en) 2000-08-23
EP0960139B1 EP0960139B1 (en) 2004-02-04

Family

ID=21894009

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98904880A Expired - Lifetime EP0960139B1 (en) 1997-02-04 1998-02-04 Elastomer treatment process to decrease peroxide levels

Country Status (11)

Country Link
US (1) US6248841B1 (en)
EP (1) EP0960139B1 (en)
JP (1) JP4214215B2 (en)
AT (1) ATE258939T1 (en)
AU (1) AU746010B2 (en)
CA (1) CA2279898C (en)
DE (1) DE69821469T2 (en)
DK (1) DK0960139T3 (en)
ES (1) ES2216268T3 (en)
PT (1) PT960139E (en)
WO (1) WO1998033827A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858300B2 (en) * 2000-05-25 2005-02-22 Nippon Chemical Industrial Co., Ltd Red phosphorus-base flame retardant for epoxy resins, red phosphorus-base flame retardant compositions therefor, processes for the production of both, epoxy resin compositions for sealing for semiconductor devices, sealants and semiconductor devices
GB0025092D0 (en) * 2000-10-13 2000-11-29 Glaxo Group Ltd Medicament dispenser
WO2003049786A2 (en) * 2001-12-07 2003-06-19 Glaxo Group Limited Metering valve and pharmaceutical metered dose inhaler and methods thereof
CA2534985A1 (en) 2003-08-11 2005-02-24 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
GB2475885B (en) * 2009-12-03 2015-04-29 Consort Medical Plc Seal for a dispensing apparatus
GB201701669D0 (en) * 2017-02-01 2017-03-15 Norton (Waterford) Ltd Quality control method for moulded plastics components

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974117A (en) * 1973-11-02 1976-08-10 Hoechst Aktiengesellschaft Process for the manufacture of aqueous copolymer dispersions
US5550211A (en) * 1991-12-18 1996-08-27 Schering Corporation Method for removing residual additives from elastomeric articles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925333A (en) 1966-06-17 1975-12-09 Goodrich Co B F Olefinic polymers of methyl-tricyclo-3,8-decadiene
NL130667C (en) 1966-10-13
US3607830A (en) 1968-10-30 1971-09-21 Stauffer Chemical Co Carrier medium for liquid n,n'polythi-bis-dialkylamine
USRE32028E (en) * 1971-08-12 1985-11-12 Uniroyal, Inc. Dynamically partially cured thermoplastic blend of monoolefin copolymer rubber and polyolefin plastic
US3957919A (en) * 1974-09-24 1976-05-18 Copolymer Rubber & Chemical Corporation Thermoplastic elastomer composition and method for preparation
KR100349699B1 (en) 1994-01-18 2003-10-04 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Pressure Sensitive Adhesive Compositions and Products thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974117A (en) * 1973-11-02 1976-08-10 Hoechst Aktiengesellschaft Process for the manufacture of aqueous copolymer dispersions
US5550211A (en) * 1991-12-18 1996-08-27 Schering Corporation Method for removing residual additives from elastomeric articles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9833827A1 *

Also Published As

Publication number Publication date
DK0960139T3 (en) 2004-05-10
EP0960139A4 (en) 2000-08-23
CA2279898A1 (en) 1998-08-06
CA2279898C (en) 2005-10-18
ATE258939T1 (en) 2004-02-15
JP2001512499A (en) 2001-08-21
WO1998033827A1 (en) 1998-08-06
DE69821469D1 (en) 2004-03-11
PT960139E (en) 2004-05-31
ES2216268T3 (en) 2004-10-16
EP0960139B1 (en) 2004-02-04
DE69821469T2 (en) 2004-12-23
JP4214215B2 (en) 2009-01-28
US6248841B1 (en) 2001-06-19
AU746010B2 (en) 2002-04-11
AU6265198A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
DE2611143C2 (en)
DE60026840T2 (en) AEROSOL PRODUCTS OF STEROID SOLUTION WITH IMPROVED CHEMICAL STABILITY
EP0960139B1 (en) Elastomer treatment process to decrease peroxide levels
Bocci et al. Oxygen-ozone in orthopaedics: EPR detection of hydroxyl free radicals in ozone-treated “nucleus pulposus” material
WO1998033827A9 (en) Elastomer treatment process to decrease peroxide levels
DE2226105C2 (en) Vulcanizable compounds
JPH07508556A (en) High purity thiol-ene composition
KR20010088444A (en) Compositions for shortstopping free radical emulsion polymerizations and stabilizing latices made therefrom
EP3135311B1 (en) Surface modification method and surface-modified elastic body
DE2739666A1 (en) METHOD OF COMBINING ANTIOXIDIZING AGENTS WITH POLYMERIC MATERIALS
DE2812951A1 (en) LIQUID POLYMERISATES CONTAINING HYDROXYL GROUPS AND PROCESS FOR THEIR PRODUCTION
Kraus et al. Chlorination of natural and synthetic polyisoprenes
Studebaker Lithium aluminum hydride analysis of sulfur-cured vulcanizates
Kleeberger et al. The role of mediators in the response of the canine peripheral lung to 1 ppm ozone.
Tucker The reaction of ozone with rubber
Srisankar et al. Reactions of ozone with fatty acid monolayers: A model system for disruption of lipid molecular assemblies by ozone
EP3228638A1 (en) Surface modification method
Said Peroxide prevulcanization of natural rubber latex
Yamana et al. Physicochemical properties of β-lactam antibacterials: Deuterium solvent isotope effect on penicillin G degradation rate
JP2004523528A (en) Degradation-resistant glucocorticosteroid preparation
Valles et al. Radioprotectors as late preventive agents against carbon tetrachloride induced liver necrosis: protection by 2-(3-aminopropylamino) ethylphosphorothioic acid (WR2721)
CH632411A5 (en) USE OF 2-BROMO-2-CHLORO-1,1,1-TRIFLUORETHANE-D AS A COMPONENT IN AN ANESTHETICAL AGENT.
Haider Mussa et al. Electrochemical degradation of metoprolol using graphite-PVC composite as anode: Elucidation and characterization of new by-products using LC-TOF/MS
Zapp et al. Stability of the vulcanized cross link in butyl rubber: Theory and application
TW454022B (en) A method of removing metal residues from a polymer cement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 19990819;SI PAYMENT 19990819

A4 Supplementary search report drawn up and despatched

Effective date: 20000706

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS PRODUCTS INC.

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS INC.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69821469

Country of ref document: DE

Date of ref document: 20040311

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040400854

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20040331

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2216268

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

26N No opposition filed

Effective date: 20041105

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20130125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCOW

Free format text: NEW ADDRESS: 55 CORPORATE DRIVE, BRIDGEWATER NEW JERSEY 08807 (US)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFUS

Owner name: AVENTISUB LLC, US

Free format text: FORMER OWNER: AVENTIS PHARMACEUTICALS INC., US

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: AVENTISUB LLC

Effective date: 20160915

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: AVENTISUB LLC; US

Effective date: 20160804

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: AVENTISUB LLC; US

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN; FORMER OWNER NAME: AVENTIS PHARMACEUTICALS INC.

Effective date: 20160826

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 258939

Country of ref document: AT

Kind code of ref document: T

Owner name: AVENTISUB LLC, US

Effective date: 20160902

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: AVENTISUB LLC, US

Effective date: 20170103

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170131

Year of fee payment: 20

Ref country code: GR

Payment date: 20170113

Year of fee payment: 20

Ref country code: CH

Payment date: 20170214

Year of fee payment: 20

Ref country code: FI

Payment date: 20170209

Year of fee payment: 20

Ref country code: FR

Payment date: 20170112

Year of fee payment: 20

Ref country code: MC

Payment date: 20170103

Year of fee payment: 20

Ref country code: SE

Payment date: 20170213

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170201

Year of fee payment: 20

Ref country code: BE

Payment date: 20161228

Year of fee payment: 20

Ref country code: LU

Payment date: 20170204

Year of fee payment: 20

Ref country code: AT

Payment date: 20170125

Year of fee payment: 20

Ref country code: NL

Payment date: 20170210

Year of fee payment: 20

Ref country code: IE

Payment date: 20170209

Year of fee payment: 20

Ref country code: DK

Payment date: 20170210

Year of fee payment: 20

Ref country code: PT

Payment date: 20170203

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20170112

Year of fee payment: 20

Ref country code: IT

Payment date: 20170221

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69821469

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20180204

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20180203

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20180203

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: AVENTISUB LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: AVENTIS PHARMACEUTICALS INC.

Effective date: 20170111

Ref country code: BE

Ref legal event code: MK

Effective date: 20180204

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 258939

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180204

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180204

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180203

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180205